Lineage Cell Therapeutics, Inc.
LCTX.TA
Get informed when a big investor buys or sells
+ FollowMarket Cap$747.65M
Close$
Share Statistics
| Market cap | $747.65 Million |
|---|---|
| Enterprise Value | $714.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.28 |
| Beta | 1.55 |
| Outstanding Shares | 249,499,000 |
Return
| Return on Equity | -53.95% |
|---|---|
| Return on Assets | -30.37% |
| Return on Invested Capital | -16.68% |
Valuation & Multiples
| P/E Ratio | -7.09 |
|---|---|
| PEG | 6.76 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 54.6 |
| Enterprise Value to EBIT | -43.6 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$5.48 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$7.13 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lineage Cell Therapeutics Inc
75 employees
CEO: Brian Culley Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecti...